Year: 2023

        Company Announcement No 34/2023Peberlyk 46200 AabenraaDenmark Tel +45 74 37 37 37Fax +45 74 37 35 36 Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk23 October 2023  Dear Sirs Sydbank share buyback programme: transactions in week 42On 6 July 2023 Sydbank announced a share buyback programme of DKK 600m. The share buyback programme commenced on 10 July 2023 and will be completed by 31 January 2024. The purpose of the share buyback programme is to reduce the share capital of Sydbank and the programme is executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, collectively referred to as the Safe Harbour rules. The following transactions have been made under the share buyback...

Press Release Nokia introduces industry’s first carrier-grade Wi-Fi 7 product portfolioNokia unveils extensive portfolio of carrier-grade Wi-Fi 7 broadband devices to the market that are more than 3x faster than Wi-Fi 6.   New portfolio of Wi-Fi 7 products includes a dual-band 5G FWA gateway, a tri-band fiber ONT gateway, and the flagship Beacon 24, a quad-band device that can provide a total Wi-Fi capacity of up to 24Gbps.    All Wi-Fi 7 products are powered by Nokia’s Corteca software, allowing CSPs to monetize new services, delivering a better user experience, and reducing their operational expense.23 October, 2023Espoo, Finland – Nokia today announced a new carrier-grade portfolio of Wi-Fi 7 devices that ensure end-users receive the ultimate broadband experience, whether they’re streaming, online gaming, or doing video calls. Supporting...

Planegg/Martinsried, October 23, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard) an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, presents data showing significantly enhanced T cell activity when combining the PD1-41BB costimulatory switch protein (CSP) with recombinant T cell receptors (rTCR) not only when directed at the cancer-testis antigen (CTA) New York esophageal squamous cell carcinoma-1 (NY-ESO-1)/L Antigen Family Member-1a (LAGE-1a), but also, presented here for the first time, against the neoantigen mutant Kirsten rat sarcoma virus (mKRAS) G12V at the ESMO Congress 2023 held October 20-24, 2023, in Madrid, Spain. The poster with the title “Mitigation of Tumor Microenvironment-Mediated Immunosuppression Using a PD1-41BB Switch Protein...

KRAKOW, Poland, Oct. 23, 2023 (GLOBE NEWSWIRE) — Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today updated clinical Phase I data from RVU120 Phase I/II study in patients with relapsed/refractory metastatic or advanced solid tumors, presented at the European Society for Medical Oncology (ESMO) Congress 2023, taking place October 20-24 in Madrid, Spain. The Company has also provided an update on the progress of the ongoing Phase Ib study in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (HR-MDS), and presented the updated RVU120 program development plan. Based on the recently updated Phase I study results in patients with solid tumors presented at ESMO, along...

Aspo PlcPress releaseOctober 23, 2023 at 09:30 Aspo’s subsidiary Leipurin divests its bakery equipment trading business Aspo’s subsidiary Leipurin has signed an agreement for the sale of its bakery equipment trading business to Orat Oy. Orat Oy is a Finnish family business specializing in import of machinery, accessories and raw materials used in the food industry and is part of Oy Transmeri Group Ab group. Leipurin bakery equipment trading business serves Finnish bakeries and other food industry companies with production equipment as well related services and spare parts. The transaction price is approximately EUR 500 thousand and includes the business and related inventory. Closing of the transaction requires certain approvals of business partners and is expected to take place by the end of the year. “We are happy to have found a new...

Strategic Collaborator-presented Phase 1 Pancreatic Cancer DataAn ongoing Phase 1, collaborator-led study of NBTXR3 in locally advanced pancreatic cancer (LAPC) established a favorable safety profile and recommended dose 23 months median Overall Survival (mOS) observed in 17 patients treated with cytotoxic chemotherapy followed by RT-activated NBTXR3 Review of an historical control from the same center as this Phase 1 in 243 patients with LAPC showed an mOS of 19.2 months in 144 patients who received cytotoxic chemotherapy followed by RT with or without concurrent or maintenance chemotherapy (80% received RT with concurrent chemotherapy) The investigator concluded that these results suggest promising anti-tumor efficacy for NBTXR3 in LAPCNanobiotix-presented Study 102 Exploratory AnalysisNew exploratory analysis of completed Study...

Malmö – ZetaDisplay AB (publ) today announce that Per Mandorf will be stepping down from his role as CEO after more than 4 successful years. During his tenure, ZetaDisplay has delivered impressive organic growth, made several acquisitions, expanded into new markets and geographies, and consolidated its leading market position in digital signage across the Nordics and Europe. “The journey with ZetaDisplay has been amazing. Over the years we’ve achieved and accomplished so many things: strong results, several acquisitions, new market entries, business development, and deployment of high-quality, customer projects and solutions – all of which have created a strong platform for further growth. None of this would have been possible without a great team with exceptional talents. The time has now come for me to leave ZetaDisplay.”, comments...

Terranet and Nihat Kücük, the CTO, have mutually agreed to part ways. The purpose is to accelerate the product development of BlincVision, and the previously communicated timetable remains. A permanent replacement is expected to be in place shortly. Recruitment of a new CTO from the automotive industry is ongoing and is expected to be completed shortly. Until then, the development work is led by the CEO, Magnus Andersson together with external advisors, and the Company’s Team Lead, who has extensive experience from the automotive industry’s subcontractor Bosch. “We need to ensure that we have the skills required to take the next step with the product and that we do it according to plan, which the market expects. We continue to strengthen with expertise at all levels of the company.” says Magnus Andersson, CEO of...

October 23, 2023, Oslo, Norway: An English arbitration tribunal has over the weekend provided a decision in PGS’s favor regarding a dispute over transfer fees under several data license agreements. In 2022, PGS recorded revenues of approximately $30 million of transfer fees relating to a change of control event under several data license agreements, where the amount was still not agreed with the client. Given the inability to timely conclude the negotiations, PGS initiated two separate arbitration proceedings under the dispute resolution provisions in the agreements. The tribunal in the first arbitration proceeding has now issued a decision in PGS’s favor. The award includes late payment interest and reasonable legal costs. The amount due to PGS, net of any revenue share to third parties, is estimated to be approximately $40 million. The...